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Eo si nop hil ca tio nic pro tein (ECP) is a he te ro ge neous mo le cu le ori gi na ti ng from ac ti va ted eo si nop hil gra nu lo cytes. Bio lo gi cal ac ti vi ty and the cel lu lar 
con te nt of ECP are de ter mi ned by ge ne tic and pos ttran sla tio nal fac to rs. Se ve ral sin gle nuc leo ti de po lymor phis ms (SNPs) in hu man ECP ge ne (RNA-
SE3) ha ve been des cri bed so far. ECP is a me dia tor in ho st im mu ne res pon se to pa ra si tes, bac te ria and vi ru ses. By its cyto toxic and no n-cyto toxic 
ac ti vi ty, ECP may al so cau se si de-eff ec ts in the hos t’s own tis sues. The lar ge st num ber of cli ni cal stu dies is fo cu sed on the ro le of ECP in eo si nop hi l-
re la ted di sor de rs, par ti cu lar ly in as thma. Al thou gh pre se nt in nu me rous bo dy fl ui ds, diffi   cu lt bioa vai la bi li ty of bio lo gi cal ma te rial, in va si ve sam pli ng 
met ho ds and com plex sam ple ma na ge me nt prior to ECP le vel de ter mi na tion are the rea so ns that se rum is mo st com mon ly used in rou ti ne la bo ra-
to ry prac ti ce. As nu me rous bio lo gi cal and met ho do lo gi cal prea na lyti cal fac to rs (the type of col lec tion te st-tu be, tem pe ra tu re and du ra tion of blood 
clot ti ng, cen tri fu ga tion, he mo lysis) may aff e ct te st re su lt, the sam ple for se rum ECP de ter mi na tion shou ld be col lec ted un der stan dar di zed con di tio-
ns. Re gar di ng in ter pre ta tion of re sul ts, it is ne ces sa ry, alo ng wi th ab so lu te ECP con cen tra tion va lues, to mo ni tor chan ges in ECP con cen tra tion du ri ng 
the du ra tion of di sea se or af ter im ple men ted the ra py, and in ter pret ECP te st re su lt in com bi na tion wi th ot her la bo ra to ry and cli ni cal fi n din gs.
Ratio nal ap proa ch to se lec tion of new tes ts is in deed one of im por ta nt requi re men ts that me di cal wor ke rs meet to day. To enab le them to de ter mi ne 
the cli ni cal sig ni fi  can ce of ECP wi th bet ter cer tain ty, fur ther stu dies on a lar ge num ber of spe ci fi c pa tie nt grou ps are nee ded.
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Review
In tro duc tion
Eo si nop hil ca tio nic pro tein (ECP), al so known un-
der the na me ri bo nuc lea se 3 (RNa se 3), is a sin gle 
ca tio nic po lypep ti de chain con sis ti ng of 133 ami-
no aci ds, wi th isoe lec tric poi nt bei ng 10.8 due to a 
hi gh con te nt of ba sic ami no aci ds, par ti cu lar ly ar-
gi ni ne. In the pro tein struc tu re, the re are three po-
ten tial si tes for N-lin ked glyco syla tion: ami no aci ds 
57-59, 65-67, and 92-94. Due to the diff e re nt con te-
nt of car bo hydra te su bu ni ts: sia lic acid, ga lac to se 
and ace tylglu co sa mi ne, the mo le cu lar ma ss of ECP 
pro tein ran ges be tween 16 and 22 kDa (1,2). A ge-
ne for hu man ECP (RNA SE3) is lo ca ted on chro mo-
so me 14 (q24-q31). Its si ze is 1.2 kb and it is ma de 
of two exo ns: no n-co di ng exon 1 (67 bp) and co di-
ng exon 2 (667 bp), and of one in tron (230 bp) (3). 
Se ve ral sin gle nuc leo ti de po lymor phis ms (SNPs) in 
RNA SE3 ha ve been des cri bed so far whi ch de ter-
mi ne the cel lu lar con te nt and bio lo gi cal ac ti vi ty of 
the ECP pro tein (3,4). Owi ng to ge ne tic fac to rs and 
pos ttran sla tio nal reac tio ns, ECP is a ve ry he te ro ge-
neous mo le cu le (5).
ECP synthe sis and sec re tion
ECP is pre se nt in the gra nu les of eo si nop hil gra nu-
lo cytes to get her wi th the ma jor ba sic pro tein 
(MBP), eo si nop hil pe roxi da se (EPO) and eo si nop hi l 
-de ri ved neu ro toxin/ eo si nop hil pro tein X (EDN/
EPX). Ve ry sma ll amoun ts of ECP can be fou nd in 
neut rop hil gra nu lo cytes and mo no cytes (6,7).
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ECP synthe sis in eo si nop hil gra nu lo cytes be gi ns 
al rea dy at the sta ge of pro mye lo cytes in pri ma ry 
gra nu les; from the mye lo cyte sta ge, ECP is pre se nt 
on ly in the mat rix of spe ci fi c gra nu les of eo si nop-
hil gra nu lo cytes (8,9). Un sti mu la ted neut rop hil 
gra nu lo cytes can not synthe ti ze ECP, but this gra-
nu lo cyte are ab le to cap tu re ECP from the en vi ron-
me nt. Howe ver, ECP mR NA is de tec ted in neut rop-
hil gra nu lo cytes af ter cel lu lar sti mu la tion (10). In 
con tra st, mo no cytes can synthe ti ze ECP but their 
abi li ty for synthe sis is lo st du ri ng mac rop ha ge dif-
fe ren tia tion (7). 
ECP is excre ted by ac ti va ted eo si nop hil tis sue gra-
nu lo cytes. The sec re tion of ECP from eo si nop hil 
gra nu lo cytes may be in du ced in two man ne rs, i.e. 
as an ti bo dy-de pen de nt (imu nog lo bu li ns, Ig; IgG, 
IgA), and as an ti bo dy-in de pen de nt (C3 and C5 
com ple me nt com po nen ts) ac ti va tion of eo si nop-
hil deg ra nu la tion (11,12). In ter leu ki ns (IL) li ke IL-5 
and IL-3, and the gra nu lo cyte-mo no cyte co lo ny 
sti mu la ti ng fac tor (GM-CSF) ha ve po si ti ve im pa ct 
on this sec re tion. The tis sue in fi l tra ted wi th eo si-
nop hil gra nu lo cytes con tai ns two types of spe ci fi c 
eo si nop hil gra nu les: in tra cel lu lar cytop las mic eo si-
nop hil gra nu les and in ta ct extra cel lu lar eo si nop hil 
gra nu les. The re lea se of the con ten ts from in tra cel-
lu lar gra nu les oc cu rs af ter ac ti va tion of eo si nop hil 
gra nu lo cytes. Wi th re ga rd to this pro ce ss, two 
mec ha nis ms are known: the so-cal led “pie ce meal 
deg ra nu la tion” de no tes se lec ti ve sec re tion via sec-
re to ry ve sic les whi le exo cyto sis in vol ves a non se-
lec ti ve pro ce ss whi ch oc cu rs mu ch mo re ra re ly. 
Extra cel lu lar gra nu les rea ch a tis sue af ter cyto lysis 
of eo si nop hi lic gra nu lo cytes. Their sec re to ry pro-
per ties are un der the con trol of nu me rous mem-
bra ne cyto ki ne re cep to rs that enab le se lec ti ve re-
lea se of in di vi dual pro tei ns from extra cel lu lar gra-
nu les. Extra cel lu lar gra nu les ha ve been sup po sed 
to fun ction as en ti re ly in de pen de nt struc tu res and 
to ad di tio nal ly en han ce lo cal in fl am ma to ry reac-
tion (13,14). Du ri ng the excre tion of the ECP mo le-
cu le from eo si nop hil gra nu les, en zyma tic deg lyco-
syla ton oc cu rs that con ver ts the inac ti ve ECP fo rm 
wi th hi gh mo le cu lar ma ss in to a cyto toxic va ria nt 
wi th low mo le cu lar ma ss (15).
In hi bi to ry eff e ct on ECP sec re tion has been con fi r-
med for cyclos po ri ne A (an im mu no sup pres sa nt), 
dexa met ha son (an an ti-in fl am ma to ry and im mu-
no sup pres si ve drug), ra pamycin (an im mu no sup-
pres sa nt), for mo te rol (a lo ng-ac ti ng β2-a go ni st), 
and pe mi ro la st (an an ti-al ler gic drug) (16-18).
RNA SE3 po lymor phis ms
Se ven SNPs ha ve been des cri bed so far in the ECP 
ge ne, and the dis tri bu tion of in di vi dual po lymor-
phis ms diff e rs sig ni fi  can tly be tween in di vi dual po-
pu la tio ns. In Cau ca sian po pu la tio ns, three po-
lymor phis ms ha ve been mo st frequen tly iden ti-
fi ed, i.e. ECP 434(G>C), ECP 562(G>C) and ECP 
-38(C>A). The ac ti vi ty of the se po lymor phis ms is 
re la ted to the quan ti ty of synthe si zed pro tein and 
bio lo gi cal fun ction so that the po lymor phis ms ha-
ve al so been as so cia ted wi th the de ve lop me nt of 
so me pat ho lo gi cal con di tio ns (4).
ECP 434(G>C) po lymor phi sm is lo ca ted in the 
RNASE3 co di ng re gion. Due to G>C sub sti tu tion, 
the co don for the ami no acid ar gi ni ne is chan ged 
in the co don for threo ni ne, whi ch lea ds to the 
chan ge in Ar g97Thr in the ECP pro tein. The con-
sequen ce of the chan ge in ami no acid struc tu re is 
al te ra tion of bio lo gi cal ac ti vi ty of the ECP mo le cu-
le be cau se Ar g97 is im por ta nt for the cyto toxic ac-
ti vi ty of ECP (19,20). The sub sti tu tion of ar gi ni ne at 
po si tion 97 wi th threo ni ne al lows the for ma tion of 
a new, four th glyco syla tion si te at po si tion 95 (EC-
P95Asn), and en han ced glyco syla tion of ECP pro tein 
dec rea ses its cyto toxic ac ti vi ty. Stu dies of re com-
bi na nt ECP97Thr have showed that, af ter deg lyco-
syla tion, it be co mes cyto toxi cal ly ac ti ve li ke EC-
P97Arg (20). Pa ra si ta ry in fec tio ns, as thma and ma lig-
na nt di sea ses are on ly so me pat ho lo gi cal con di tio-
ns wi th ECP in vol ve me nt in their pat ho mec ha nis-
ms so that di sea se out co me is as so cia ted wi th ECP 
phe no type or ge no type. Thus, in di vi dua ls in fec ted 
wi th Schis to so ma man so ni (S. man so ni) pa ra si te, 
who are at the sa me ti me car rie rs of the ECP 434GG 
cyto toxic ge no type, ha ve bet ter pri ma ry de fen se 
reac tion com pa red wi th in fec ted in di vi dua ls wi th 
ot her ge no types, but al so de ve lop con si de rab ly 
mo re frequen tly a se rious and li fe-threa te ni ng 
com pli ca tio ns li ke he pa tic fi b ro sis (19). The pre va-
len ce of in di vi dual ECP 434 ge no type in pa tien ts 
wi th al ler gic di sea ses de mon stra tes et hnic and 
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gen der va ria bi li ty (21). Pa tien ts wi th al ler gic as-
thma ha ve 434GG (ECP97Arg) ge no type con si de rab-
ly mo re of ten than no n-al ler gic as thma ti cs. It has 
al so been ob ser ved that the com bi na tion of ato-
pia and 434GG (ECP97Arg) ge no type con si de rab ly 
in crea ses the ri sk for de ve lop me nt of al ler gic ma-
ni fes ta tio ns. Howe ver, as the frequen cy of as thma-
tic pa tien ts is not in crea sed amo ng in di vi dua ls wi-
th 434GG (ECP97Arg) ge no type, the po lymor phi sm 
has no pre dic ti ve va lue for the de ve lop me nt of as-
thma (22). The as so cia tion of ECP 434GG ge no type 
and the oc cur ren ce of al ler gic sympto ms is explai-
ned by the cyto toxic ac ti vi ty of ECP97Arg in epit he-
lial cel ls in the no se and lun gs of pa tien ts wi th al-
ler gic rhi ni tis and al ler gic as thma (4). Al so, a re la-
tion ship has been des cri bed be tween ECP 
434(G>C) po lymor phi sm and lu ng fun ction. Thus, 
wo men who we re 434GG ge no type car rie rs had 
dec rea sed pul mo na ry fun ction, whi ch can be ac-
coun ted for by the fa ct that cyto toxic ac ti vi ty of 
ECP97Arg may des troy lu ng epit he lial cel ls (21).
Patien ts wi th ma lig na nt di sea ses ha ve in fl am ma-
to ry ce ll in fi l tra tion arou nd tu mor tis sue; the ta sk 
of the se cel ls is an ti-tu mor ac tion so that tu mo r-as-
so cia ted tis sue eo si nop hi lia (TATE) is as so cia ted wi-
th bet ter di sea se prog no sis (23,24). Howe ver, ot her 
stu dies ha ve shown that the TATE has a poor prog-
no sis or that eo si nop hi ls ha ve an im por ta nt ro le in 
tu mor prog res sion (25-27). Un der di ver se sti mu li 
the eo si nop hi ls are ab le to in du ce or in hi bit the tu-
mor des truc tion (27). The as so cia tion be tween 
TATE and ECP po lymor phis ms is new in sig ht in to 
the ro le of eo si nop hi ls in ma lig na nt di sea ses. Ac-
cor di ng to Pe rei ra and col lea gues (28), pa tien ts wi-
th oral squa mous ce ll car ci no mas who are the car-
rie rs of no n-cyto toxic ECP 434CC ge no type ha ve a 
poor cli ni cal out co me des pi te tu mo r-as so cia ted 
tis sue eo si nop hi lia. In ad di tion, re sear ch on tu mor 
ce ll li nes in vit ro de mon stra ted re du ced an ti tu mor 
cyto toxic ca pa ci ty of re com bi na nt ECP97Thr.
ECP 562(G>C) po lymor phi sm is lo ca ted in the 3’-
untranslated re gion of RNA SE3. The in tra cel lu lar 
con cen tra tion of ECP was sig ni fi  can tly lower in eo-
si nop hil gra nu lo ci tes from sub jec ts wi th ECP 
562CC ge no type but a re la tion ship has not been 
des cri bed be tween the 562(G>C) po lymor phi sm 
and al ler gy (29). The po ten tial re la tion ship be-
tween the 3’-untranslated re gion and expres sion 
of mR NA ha ve been des cri bed in ot her ge nes (30). 
A pos sib le expla na tion for 562(G>C) po lymor phi-
sm and cel lu lar ECP con te nt cou ld be al te ra tio ns in 
the mR NA sta bi li ty.
ECP -38(C>A) po lymor phi sm is lo ca ted in the fi r st 
RNA SE3 in tron in the re gion of the bin di ng si te for 
the glo bin tran scrip tion fac to r-1 (GA TA-1) whi ch re-
gu la tes the de ve lop me nt of eo si nop hi lic gra nu lo-
cytes. Mo reo ver, po si tion -38 is lo ca ted in the 
proxi mi ty of the bin di ng si te for the nuc lear fac tor 
of ac ti va ted T-cel ls (NFAT). Bo th of the se bin di ng 
si tes are im por ta nt sin ce they aff e ct pro mo ter ac ti-
vi ty of RNA SE3 as the so-cal led in tro n-en han cer 
ele men ts. -38A al le le has been as so cia ted wi th in-
te rin di vi dual va ria tion in se rum ECP le ve ls (31). Al-
so, the car rie rs of -38A al le le mo re frequen tly ha ve 
se rum ECP con cen tra tion hig her than 16 μg/L and 
de ve lop al ler gic as thma mo re frequen tly than -38C 
al le le car rie rs.
Po pu la tion stu dies of RNA SE3 po lymor phis ms ha-
ve so far been per for med on a sma ll num ber of 
sub jec ts, i.e. in di vi dual pa tie nt grou ps. For this rea-
son, it is diffi   cu lt to in ter pret con tra dic to ry re sul ts 
be tween in di vi dual grou ps ob ser ved, and to ap ply 
them in rou ti ne cli ni cal prac ti ce.
As mo st po lymor phis ms con tri bu te to phe no type 
on ly mo de ra te ly, mul ti cen tric stu dies of va rious 
sub je ct grou ps, i.e. the ge no me wi de as so cia tio ns 
(GWA) are ne ces sa ry in or der to re veal the ac tual 
cau sa ti ve re la tion ship be tween SNP and phe no-
type. A po lymor phi sm may ve ry of ten con tri bu te 
to a phe no type on ly in in te rac tion wi th ot her po-
lymor phis ms, that is, a cer tain po lymor phi sm has 
diff e re nt eff e ct on the phe no type de pen di ng on 
the deg ree of expo su re of an in di vi dual to a par ti-
cu lar en vi ron men tal fac tor. All this in di ca tes that 
fur ther stu dies are yet ne ces sa ry for bet ter un der-
stan di ng of the ro le of ECP po lymor phi sm on the 
de ve lop me nt of cer tain pat ho lo gi cal con di tio ns.
ECP and its mec ha ni sm of ac tion
ECP exhi bi ts nu me rous bio lo gi cal ac ti vi ties that 
may be clas si fi ed in to reac tio ns wi th cyto toxic ef-
fe ct and tho se wi th no n-toxic eff e ct.
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Cyto toxic ac ti vi ty of ECP is eff ec ti ve again st a wi de 
ran ge of mic roor ga nis ms: pa ra si tes, Gra m-ne ga ti-
ve and Gra m-po si ti ve bac te ria, vi ru ses (32-34). Al-
thou gh an ti mic ro bial ac ti vi ty of ECP in in vi vo con-
di tio ns is sti ll in ten si ve ly in ves ti ga ted, re sul ts of in 
vit ro in ves ti ga tio ns in di ca te un spe ci fi c mec ha nis-
ms of ac tion (35).
The da ta gat he red are on ly in di vi dual puz zles that 
are yet to be pie ced to get her in to the fi  nal mec ha-
ni sm of cyto toxic ac tion.
An ti bac te rial ac ti vi ty
For an ti bac te rial ECP ac ti vi ty, elec tros ta tic in te rac-
tio ns are im por ta nt be tween ne ga ti ve ly char ged 
cel lu lar mem bra ne or cel lu lar bac te rial wa ll and 
po si ti ve ly char ged ECP, fol lowed by des ta bi li za tion 
of bac te rial mem bra ne. Ot her mec ha nis ms in vol ve 
par tial in ser tion of ECP in to li pid bi laye rs and for-
ma tion of tran smem bra ne po res that al low the 
tran si tion of wa ter and os mo tic ce ll lysis. Spe ci fi c 
in te rac tion of ECP wi th li po po lysac cha ri des and 
pep ti dog lyca ns on the bac te rial ce ll wa ll may re su-
lt in bac te rial ce ll ag gre ga tion and ce ll dea th (35-
39).
An ti hel min thic ac ti vi ty
The cor re la tion be tween ECP and an ti hel min thic 
ac ti vi ty is ba sed on the in for ma tion that eo si nop-
hi lia is pre se nt in the pe rip he ral blood of pa tien ts 
wi th pa ra si ta ry di sea ses and gra nu lo cyte and eo si-
nop hil in fi l tra tes ha ve been de tec ted in tis sue 
biop sy. Howe ver, the ac tual ro le of ECP and eo si-
nop hil gra nu lo cytes in pa ra si ta ry in fec tion has not 
been cla ri fi ed. So me stu dies ha ve sug ges ted that 
eo si nop hil gra nu lo cytes act on pa ra si tes on ly in 
their in fec ti ve lar val sta ges, but not on adu lt for ms 
(40). As pa ra si ta ry di sea ses usual ly ha ve chro nic 
cour se, their pat ho mec ha ni sm de pic ts adap ta tio-
nal pro ces ses, that is, tis sue da ma ges are not the 
con sequen ce of ac tion of a pat ho ge nic age nt it se lf 
but rat her oc cur due to ho st im mu ne res pon se. 
One of the for ms of su ch im mu ne res pon se is iso-
la tion of pat ho ge nic age nt and the en ti re in fec ted 
re gion in the fo rm of gra nu lo ma. Blood cel ls, par ti-
cu lar ly eo si nop hil gra nu lo cytes, are pa rt of the 
struc tu re of su ch gra nu lo mas. Over ti me, so me pa-
tien ts de ve lop fi b ro tic plaques, wi th ECP as a me-
dia tor in their for ma tion. The mec ha ni sm by whi ch 
ECP me dia tes the re mo de li ng of the extra cel lu lar 
mat rix is ini tia ted by the che mo tac tic ac tion of ECP 
on fi b rob las ts. In ad di tion, ECP sti mu la tes the 
excre tion of a pro-fi b ro tic me dia tor from fi b rob las-
ts, the tumor growth fac to r-β (TGF-β) (41).
An ti vi ral ac ti vi ty
An ti vi ral ac tion of ECP is me dia ted by ri bo nuc lea se 
ac ti vi ty. Ac tual ly, ECP be lon gs to the fa mi ly of ri bo-
nuc lea ses A (RNa se A) whi ch, as exo- and/or en do-
nuc lea se, clea ve the sin gle-stra nd RNA mo le cu les. 
Ri bo nuc lea se ac ti vi ty of the ECP mo le cu le is con si-
de rab ly lower than the EDN mo le cu le (34,42). Ri-
bo nuc lea se ac ti vi ty is, howe ver, the sa me in all ge-
ne tic and pos ttran sla tio nal ECP va rian ts and is en-
ti re ly in de pen de nt of cyto toxic ac ti vi ty. The lar ge-
st num ber of stu dies of the mec ha ni sm of an ti vi ral 
ECP ac tion ha ve been per for med on res pi ra to ry 
syncytial vi rus (RSV) be cau se of its si ze (15.2 kb) 
and struc tu re (sin gle-stran ded RNA ge no me) 
(43,44). Re sul ts of in vit ro in ves ti ga tio ns showed 
that ECP lowe rs vi ral in fec ti vi ty, yet ri bo nuc lea se 
ac ti vi ty it se lf - al thou gh im por ta nt, - is not suffi   cie-
nt for fu ll an ti vi ral eff e ct that is at tri bu ted to eo si-
nop hil gra nu lo cytes (42).
Be cau se of its an ti-in fec ti ve pro per ties, ECP has 
pos sib le the ra peu tic po ten tial in the drug de ve-
lop me nt in dus try. E CP-pep tid (1-45) re tai ns the 
ECP na ti ve pro tein cyto toxi ci ty again st bac te ria 
and mem bra ne dis rup ti ng ac ti vi ties, too. Fur the-
mo re, E CP-pep tid (1-45) ful fi  ls the com mon cri te ria 
for an ti mic ro bial pep ti de as al ter na ti ve an ti bio ti cs 
(45,46). Un der stan di ng spe ci fi c in te rac tio ns be-
tween pat ho ge nic agen ts and an ti mic ro bial pro-
tei ns cou ld be aid in de sig ni ng new an ti mic ro bial 
dru gs, par ti cu lar ly at in the se ti mes of in crea si ng 
re sis tan ce again st an ti bio ti cs.
An ti ho st ac ti vi ty
In ad di tion to its im por ta nt ro le in ho st im mu ne 
de fen se, ECP may via its cyto toxic ac ti vi ty al so cau-
se un de si red si de-eff ec ts on the hos t’s own tis-
sues. Neu ro nal da ma ge (Gor do n’s phe no me non) 
has been des cri bed, as we ll as the da ma ge of mus-
cu lar cel ls and res pi ra to ry tra ct epit he lial cel ls. If 
the eff e ct of ECP cou ld be ma ni fes ted on eu ka ryo-
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tic cel ls, spe ci fi c bin di ng of the ECP mo le cu le on 
the ce ll sur fa ce of he pa ran sul fa te pro teog lyca ns 
wou ld be of cru cial im por tan ce. One of the pos sib-
le mec ha nis ms of eo si nop hi l-in du ced tis sue des-
truc tion is ba sed on the apop to tic ac tion of ECP 
via ac ti va tion of the cas pa se cycle (35,47-49). In 
con tra st, in tra cel lu lar ac cu mu la tion of ECP mo le-
cu les is cri ti cal for der mal ce ll da ma ge in nu me-
rous der ma to ses, whi le the pat ho mec ha ni sm of 
skin le sio ns is ba sed on RNa se ac ti vi ty and ca tio n-
de pen de nt cyto toxi ci ty of the ECP mo le cu le (50).
No n-toxic ac ti vi ty
No n-toxic ac tion of ECP in vol ves nu me rous im mu-
no mo du la to ry ac ti vi ties and so me aut ho rs ad vo-
ca te the hypot he sis that the pri ma ry in vi vo ro le of 
the ECP mo le cu le is exac tly the ge ne ral ho st de-
fen se. So me im mu no mo du la to ry ac ti vi ties are in-
hi bi tion of T-ce ll pro li fe ra tion, up re gu la tion of re-
cep to rs and ad he sion mo le cu les on epit he lial cel ls, 
or ba sop hil his ta mi ne re lea se (2,35,41). Spe cifi c re-
gion of ECP ac tion is tis sue re mo de li ng whi ch has 
been par ti cu lar ly stu died on the mo del of as thma. 
ECP ac tion in tis sue re pair pro ces ses be gi ns wi th 
che mo tac tic ac tion on fi b rob las ts. Mo reo ver, ECP 
sti mu la tes the excre tion of TGF-β, a fac tor wi th 
pro-fi b ro tic ac tion who se ac ti vi ty is ma ni fes ted in 
al te ri ng the in tra cel lu lar me ta bo li sm of fi b rob las ts. 
In ad di tion to en han ced pro teog lycan synthe sis, 
ECP al so me dia tes the in hi bi tion of pro teog lycan 
deg ra da tion, wi th re sul ti ng in tra cel lu lar pro teog-
lycan accu mu la tion (41,51). Car dio lo gy is a new 
bran ch of me di ci ne that has, sin ce not lo ng ago, 
been dea li ng wi th the con sequen ces of ECP ac ti vi-
ty on at he ro ge ne sis. Thus, ECP enab les ad he sion 
of mo no cytes on en dot he lial cel ls, is in vol ved in 
coa gu la tion cas ca de, and has a sta bi li zi ng im pa ct 
on the plaque (2, 41, 51).
Cli ni cal sig ni fi  can ce of ECP
Only ac ti va ted eo si nop hil gra nu lo cytes re lea se the 
gra nu le con te nt and the re fo re the de ter mi na tion 
of ECP con cen tra tion is a con si de rab ly mo re spe ci-
fi c in di ca tor of eo si nop hil in fl am ma tion that eo si-
nop hil gra nu lo cyte cou nt in pe rip he ral blood. ECP 
has been as so cia ted wi th se ve ral pat ho lo gic con-
di tio ns. The lar ge st num ber of cli ni cal stu dies deal 
wi th ato pic di sea ses: as thma, al ler gic rhi ni tis, ato-
pic eczema/dermatitis syndro me (AEDS) (53-56). 
Ele va ted se rum va lues are pro por tio nal to the in-
ten si ty of al ler gic in fl am ma tion and in di ca te acu te 
al ler gen expo su re. In ad di tion, diag nos tic and 
prog nos tic ro le of ECP is in ves ti ga ted al so in ot her 
eo si nop hi l-re la ted di sea ses li ke in fec ti ve di sea ses, 
res pi ra to ry di sor de rs, in fl am ma to ry in tes ti nal di-
sea ses, ma lig nan cies wi th eo si nop hi lia (27,57-61).
ECP and as thma
ECP has been in ten si ve ly stu died as a po ten tial 
mar ker of as thma sin ce the sec re to ry ac ti vi ty of 
eo si nop hil gra nu lo cytes, par ti cu lar ly the re lea se of 
deg ra nu la tion pro duc ts, is an im por ta nt com po-
ne nt of as thma pat hop hysio lo gy. Ba sic pro tei ns 
from eo si nop hil gra nu les in du ce tis sue da ma ge, 
ai rway in fl am ma tion and ai rway re mo de li ng. 
Howe ver, ECP has no im pa ct on the re lea se of 
bron choac ti ve me dia to rs and ai rway hype r-res-
pon si ve ne ss (62,63).
Se rum ECP le vel in as thma tic pa tien ts cor re la tes 
wi th the biop sy fi n di ng of eo si nop hil gra nu lo cytes 
in the ai rway mu co sa and wi th the cli ni cal da ta. Al-
thou gh a lar ge num ber of stu dies ha ve con fi r med 
the as so cia tion of ECP wi th as thma, ECP de ter mi-
na tion is not a sui tab le diag nos tic mar ker of as-
thma be cau se chan ges in se rum ECP le vel ha ve 
been re gis te red in ot her ato pic di sea ses li ke al ler-
gic rhi ni tis, but al so in con di tio ns not re la ted to the 
eo si nop hil in fl am ma tion li ke bac te rial si nu si tis 
(54,56). Mo reo ver, eo si nop hil gra nu lo cytes and 
ECP are pa ra me te rs who se ap pli ca tion is li mi ted 
on ly to the al ler gic type of as thma.
Howe ver, as ECP con cen tra tion in tis sue and bo dy 
fl ui ds cor re la tes wi th di sea se ac ti vi ty, ECP may aid 
in as ses si ng the se ve ri ty of as thma and in reac hi ng 
a de ci sion on the ra py type and in ten si ty (54,55), 
par ti cu lar ly in chil dren be cau se of freque nt dis cre-
pan cy be tween physi cia n’s as ses sme nt and the 
chil d’s sub jec ti ve expe rien ce of di sea se. By fol lowi-
ng-up chan ges in the ECP le vel af ter in tro duc tion 
of the ra py, it is pos sib le to mo ni tor effi   cien cy of a 
spe ci fi c drug do se and to cor re ct do sa ge to avoid 
over do si ng or as thma at ta ck be cau se of a too low 
Biochemia Medica 2011;21(2):111-21
116
Zrin ski To pic R, Do dig S. ECP – cur re nt con cep ts and con tro ver sies
do se, all wi th a view to main tain the we ll con trol-
led as thma sta tus.
Increa si ng se rum ECP con cen tra tion du ri ng acu te 
exa cer ba tio ns is al so of cli ni cal sig ni fi  can ce (55). 
Thus, the ele va tion of ECP le ve ls in as thma tic pa-
tien ts wi th ina dequa te the ra py poin ts to re lap se 
and acu te exa cer ba tion, and ECP de ter mi na tion 
may be used as an in di ca tor of whet her pa tien ts 
ta ke their the ra py re gu lar ly. Howe ver, exa cer ba-
tion may oc cur al so wit hout an in crea se in se rum 
ECP con cen tra tion in so me as thma tic pa tien ts at 
an ad van ced age or in pa tien ts wi th pro lon ged di-
sea se du ra tion. In con tra st to this, ele va ted ECP le-
vel ha ve been re gis te red in vi ru s-in du ced exa cer-
ba tion, wi th nor mal eo si nop hil gra nu lo cyte cou nt 
in pe rip he ral blood (64).
Mea su re me nt of eo si nop hil ac ti vi ty du ri ng the 
youn ge st yea rs may aid in pre dic ti ng the de ve lop-
me nt of as thma at school age. Thus, the chil dren 
who had been hos pi ta li zed at their ear lie st age 
due to whee zi ng in res pi ra to ry in fec tion and who-
se se rum ECP le vel was hig her than 20 μg/L had 
con si de rab ly in crea sed ri sk for the in ci den ce of 
chro nic as thma at school age (spe ci fi  ci ty 93%, sen-
si ti vi ty 30%) (65).
ECP and hype reo si nop hi lia
Hype reo si nop hi lia is a com mon la bo ra to ry fi n di ng 
that may oc cur as a con sequen ce of reac ti ve eo si-
nop hi lia (tis sue pa ra si to sis, in fl am ma to ry or al ler-
gic con di tio ns, ma lig nan cy), clo nal eo si nop hi lia 
(he ma to lo gic ma lig nan cy) or be cau se of un known 
cau se (idio pat hic hype reo si nop hi lic syndro me, 
IHES). The num ber of eo si nop hi lic gra nu lo cytes in 
pe rip he ral blood refl ec ts cur re nt ba lan ce sta tus 
amo ng cel ls re lea sed from the bo ne mar row and 
tis sue cel ls. Howe ver, the num ber of eo si nop hil 
gra nu lo cytes does not re veal anythi ng re gar di ng 
tis sue in fi l tra tion and eo si nop hil ac ti vi ty. De ter mi-
na tion of plas ma ECP con cen tra tion and the ECP/
eosinophil cou nt ra tio may pro mo te diff e ren tial 
diag nos ti cs of hype reo si nop hi lia. It has been ob-
ser ved that the va lues of ECP and of the abo ve ra-
tio we re the hig he st in pa tien ts wi th idio pat hic 
hype reo si nop hi lic syndro me (IHES), and that the se 
va lus we re hig her in pa tien ts wi th reac ti ve eo si-
nop hi lia wi th ma lig nan cy than in pa tien ts wi th 
reac ti ve eo si nop hi lia wi th in fl am ma tion. Howe ver, 
it is not pos sib le to dis tin gui sh clo nal from reac ti ve 
eo si nop hi lia on the ba sis of ECP con cen tra tion and 
ECP/eosinophil cou nt ra tio (59).
ECP and bio lo gi cal spe ci me ns
ECP is pre se nt in nu me rous bo dy fl ui ds li ke plas-
ma, se rum, spu tum, bron choal veo lar la va ge (BAL), 
sa li va, na sal la va ge, tea rs, je ju nal fl uid, fae ces, 
syno vial fl uid (2). Howe ver, the avai la bi li ty of bio lo-
gi cal ma te rial, in va si ve sam pli ng met ho ds and 
com plex sam ple ma na ge me nt prior to ECP le vel 
de ter mi na tion are the rea so ns why se rum is mo st 
com mon ly used in rou ti ne prac ti ce.
ECP in se rum and plas ma
ECP le vel in se rum is hig her than its le vel in plas ma 
be cau se an ti coa gu lan ts inac ti va te eo si nop hil gra-
nu lo cytes and blo ck deg ra nu la tion ex vi vo (66,67). 
The le vel of ECP in plas ma cor res pon ds to the ECP 
le vel in cir cu la tion du ri ng blood sam pli ng ti me, i.e. 
it rep re sen ts the diff e ren ce be tween the ECP re-
lea sed in cir cu la tion and the ECP eli mi na ted from 
cir cu la tion.
In cir cu la tion, ECP oc cu rs as a free pro tein and in 
com plex. ECP is bou nd to α2-mac rog lo bu lin 
(α2-M), and the ha lf-li fe of ECP in cir cu la tion is ap-
proxi ma te ly 45 mi nu tes (68). In ad di tion to bei ng 
the cir cu la ti ng le vel, the se rum le vel of ECP rep re-
sen ts the sec re to ry ac ti vi ty of eo si nop hil gra nu lo-
cytes du ri ng blood coa gu la tion, and the re fo re se-
rum ECP con cen tra tion (2-20 μg/L) is up to ten fo ld 
hig her than its con cen tra tion in plas ma. Se rum 
ECP le vel al lows ea sier diff e ren tia tion be tween 
heal thy and si ck sub jec ts in com pa ri son to plas ma 
ECP con cen tra tion be cau se the eff ect of the tur no-
ver of ECP in vi vo is eli mi na ted in se rum. Howe ver, 
in or der to en su re cor re ct in ter pre ta tion of se rum 
ECP con cen tra tion, it is ne ces sa ry to col le ct the 
sam ple for se rum ECP de ter mi na tion un der stan-
dar di zed con di tio ns (67,69,70). Ac tual ly, the type of 
col lec tion te st-tu be, tem pe ra tu re and du ra tion of 
blood clot ti ng, cen tri fu ga tion and he mo lysis are 
the fac to rs that may cau se fal se po si ti ve se rum ECP 
re sul ts (Tab le 1). It is the re fo re ne ces sa ry to read 
pro per ly the in struc tio ns of the rea ge nt manu fac-
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tu rer prior to sam pli ng, and to ap ply the re com-
men ded pro to col.
Serum ECP con cen tra tion in heal thy in di vi dua ls is 
cha rac te ri zed by con si de rab le in train di vi dual va-
ria tion, 27% (71). Du ri ng 24 hou rs, its va lues are 
hig her at nig ht whi le the peak se rum ECP le vel is in 
the mor ni ng at 6 o’clo ck (72). To dec rea se the im-
pa ct of cir ca dian va ria tio ns on se rum ECP con cen-
tra tion, it is, for lon gi tu di nal com pa ri son, re com-
men ded that blood sam pli ng is per for med at ap-
proxi ma te ly the sa me ti me of the day. In ad di tion 
to dai ly chan ges, sea so nal diff e ren ces in the ECP 
con cen tra tion ha ve al so been des cri bed in no n-a-
to pic chil dren (73). Mo reo ver, ge ne po lymor phis-
ms that chan ge the le vel of RNA SE3 expres sion are 
al so res pon sib le for in te rin di vi dual diff e ren ces in 
se rum ECP con cen tra tion (31).
Spu tum ECP
De ter mi na tion of ECP con cen tra tion in spu tum 
pro vi des exa ct in for ma tion on the lo cal in fl am ma-
to ry pro ce ss in pa tien ts wi th as thma, chro nic ob-
struc ti ve pul mo na ry di sea se (COPD) or cystic fi b ro-
sis (60,74-77). Mo reo ver, ECP con cen tra ton in spu-
tum (20-1280 μg/L) is con si de rab ly hig her than 
that in se rum. Howe ver, the use of spu tum as a 
rou ti ne ly ap plied bio lo gi cal ma te rial is as so cia ted 
wi th so me diffi   cul ties: the sam pli ng of spon ta-
neous ly pro du ced or in du ced spu tum, prea nalyti-
cal spu tum ma na ge me nt to se pa ra te cel ls from ot-
her con ten ts, the eff e ct of sa li va con ta mi na tion, 
over lap pi ng of nor mal and pat ho lo gi cal ran ges of 
ECP le ve ls (54,78). The re fo re, spu tum sam pli ng 
shou ld be stan dar di zed be fo re it is used in rou ti ne 
prac ti ce (79).
ECP in sa li va
ECP con cen tra tion in sa li va is 250-450 μg/L (54). 
Sali va sam pli ng is a sim ple and no nin va si ve pro ce-
du re, rea di ly ac cep tab le to chil dren. Cor re la tion 
be tween se rum ECP and sa li va ECP con cen tra tion 
is not con fi r med (80). For the rou ti ne ECP de ter mi-
na tion in sa li va it is ne ces sa ry to stan dar di ze the 
sam pli ng met hod and in ves ti ga te the cli ni cal uti li-
ty of su ch la bo ra to ry re su lt (54).
ECP in la va ge fl ui ds
ECP con cen tra tion in na sal la va ge fl uid and bron-
choal veo lar la va ge fl uid is ve ry low and the col lec-
tion of the bio lo gi cal ma te rial in vol ves in va si ve 
sam pli ng met ho ds (54). Mo reo ver, na sal la va ge 
ECP le ve ls are cha rac te ri zed by hi gh in train di vi dual 
va ria tion, 123% (81). A no vel met hod to col le ct na-
sal sec re tion by na sal sec re tion col lec tor shows 
Sam ple han dli ng fac tor ECP re su lt Re com men da tion
Blood col lec tion tu be ma te rial
Ad di ti ves
Gel
? See rea ge nt pac ka ge in struc tion be cau se on ly a few va rian ts of tu be has been tes ted.
Clot ti ng tem pe ra tu re ↑ 10-15% per 1°C Stab le room tem pe ra tu re
Clot ti ng ti me ↑ 60-120 mi nu tesor lon ger if pa tien ts re cei vi ng an ti coa gu la nt the ra py
Cen tri fu ga tion tem pe ra tu re ↑ Stab le room tem pe ra tu re
Gel bar rier ↑ 4% per hour De ca nt se rum in to new tu be wit hin 1 hour af ter cen tri fu ga tion
He mo lysis ↑ Shou ld not be used
Se rum sto ra ge gla ss tu be ↓ Polypro pyle ne or po lystyre ne tu be
Se rum sto ra ge ↓
5 days +4 °C
90 days -20 °C
or see rea ge nt pac ka ge in struc tion
ECP – Eo si nop hil ca tio nic pro tein
TAB LE 1. Eff e ct of sam ple han dli ng on the eo si nop hil ca tio nic pro tein re su lt in se rum
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nu me rous ad van ta ges over na sal la va ge met hod 
(82). This met hod cou ld be use ful tool for the ana-
lysis of na sal in fl am ma tion and for fol lowi ng diag-
nos tic and the ra peu tic in ter ven tion (83,84).
ECP in hu man stool sam ples
Fe cal ECP is in ten si ve ly in ves ti ga ted as a no vel po-
ten tial mar ker of in fl am ma to ry bowel di sea se (IBD) 
and eo si nop hil gas troen te ri tis (57,61). Pa st IBD 
diag nos ti cs was ba sed on con ven tio nal his to lo gy 
whi ch de mon stra ted the pre sen ce of eo si nop hi lic 
gra nu lo cytes in in tes ti nal mu co sa; this, howe ver, 
in vol ved an in va si ve met hod of the bio lo gi cal ma-
te rial sam pli ng, whe reas fe cal ECP de ter mi na tion 
is a no nin va si ve and chea per diag nos tic met hod. 
Mo reo ver, fe cal ECP le ve ls are not de pen de nt on 
the num ber of eo si nop hil gra nu lo cytes or se rum 
ECP va lues, whi ch ma kes this type of mea su re me-
nt a po ten tial in tes ti nal mar ker. Al so, fe cal ECP le-
ve ls do not diff er in de pen den ce to age or gen der 
(85).
Con clu sion
The ECP mo le cu le par ti ci pa tes in a lar ge num ber 
of bio lo gi cal reac tio ns, whi ch ma kes it an unac cep-
tab le diag nos tic mar ker due to low diag nos tic spe-
ci fi  ci ty. Des pi te the pro vi sion of a lar ge amou nt of 
use ful da ta (sear ch te rm ECP, a to tal of 2196 re fe-
ren ces we re iden ti fi ed from Pub Med on Ap ril 14th 
2011), all to da te cli ni cal or mo le cu lar stu dies ha ve 
been as so cia ted wi th cer tain li mi ta tio ns: sma ll 
num ber of sub jec ts (stu dies ran ged from fewer 
than 10 par ti ci pan ts to mo re than 700 par ti ci pan-
ts), in suffi   cie nt in teg ra tion of all fac to rs that may 
aff e ct in ter pre ta tion of re sul ts, va rious pro to co ls 
for pre pa ra tion of sam ples for ana lysis, diff e re nt 
ana lyti cal met ho ds for ECP le vel de ter mi na tion, 
and ma ny ot he rs. In ad di tion, ma ny con clu sio ns 
ha ve been reac hed on the ba sis of a ve ry sim pli-
fi ed ap proa ch whe re diff e re nt pat ho lo gies are sim-
pli fi ed to the le vel of di sea ses cau sed by on ly one 
type of cel ls, eo si nop hil granu lo cytes, and a sin gle 
mo le cu le, ECP. It is pre sen tly known that the 
frequen cy of eo si nop hil gra nu lo cytes and ECP 
con cen tra tion va ry in the sa me pat ho lo gi cal con-
di tion in so me pa tien ts, and that ECP expres sion is 
de pen de nt on ge ne tic and pos ttran sla tio nal fac to-
rs. The re fo re, new stu dies shou ld be de sig ned so 
as to pro vi de an swe rs to all open ques tio ns.
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Eo zi no fi l ni ka tion ski pro tein – ak tual ni kon cep ti i ras pra ve
Sažetak
Eo zi no fi l ni ka tion ski pro tein (en gl. eo si nop hil ca tio nic pro tein, ECP) je he te ro ge na mo le ku la porijeklom iz ak ti vi ra nih eo zi no fi l nih gra nu lo ci ta. 
Bio loš ka ak tiv no st i sta nič ni sad r žaj ECP od re đe ni su gen skim i pos ttran sla cij skim čim be ni ci ma. Do sada je opisano svega nekoliko promjena po-
jedine baze u nukleotidnom slijedu gena koji kodira humani ECP (RNASE3). ECP je pos red nik u imu no loš kom od go vo ru do ma ći na na pa ra zi te, bak-
te ri je i vi ru se. Zbog svo je ci to tok sič ne i ne-ci to tok sič ne ak tiv nos ti ECP može uzrokovati i neželjene reakcije u tkivu domaćina. Naj ve ći broj kli nič kih 
is tra ži va nja us re do to čen je na ulo gu ECP u po re me ća ji ma po ve za nim s eo zi no fi  li ma, po se bi ce kod as tme. Ia ko je pri su tan u broj nim tje les nim 
te ku ći na ma, slo že na dos tup no st bio loš kog ma te ri ja la, in va ziv ne me to de pri kup lja nja uzo ra ka i kom plek sna ob ra da uzo ra ka pri je od re đi va nja 
kon cen tra ci je ECP raz lo zi su zbog ko jih se u ru tin skoj la bo ra to rij skoj prak si naj češ će ko ris ti se rum.
Bu du ći da broj ni bio loš ki i me to do loš ki pri jea na li tič ki čim be ni ci (tip ep ru ve te za sa kup lja nje uzo ra ka, tem pe ra tu ra i tra ja nje zgru ša va nja kr vi, 
cen tri fu gi ra nje, he mo li za) mo gu ut je ca ti na re zul tat is pi ti va nja, uzo rak za od re đi va nje kon cen tra ci je ECP u se ru mu mo ra bi ti sa kup ljen u stan dar-
di zi ra nim uv je ti ma. Pri tumačenju nalaza potrebno je pored apsolutne vrijednosti koncentracije ECP, pratiti i promjene koncentracije ECP tijekom 
trajanja bolesti ili nakon provedene terapije te nalaz ECP tumačiti u kombinaciji s drugim laboratorijskim i kliničkim nalazima.
U nizu zahtjeva koji se postavljaju pred zdravstvene djelatnike svakako je i racionalni pristup odabiru novih pretraga. Kako bi se s većom sigurno-
šću mogla odrediti klinička značajnost ECP potrebna su daljnja istraživanja na većem broju pojedinih skupina bolesnika.
Ključ ne ri je či: eo zi no fi l ni ka tion ski pro tein; po li mor fi  zam; ci to tok sič no st; as tma
